Loading news...
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Telix Pharmaceuticals (NASDAQ: TLX) outlined its commercial imaging franchise, regulatory plans for two radiodiagnostic candidates, and progress across a broad therapeutic radiopharmaceutical pipeline during a discussion at Oppenheimer's Annual Healthcare Conference with CEO Christian Behrenbruch. Company scale and business mix Behrenbruch said Telix is dual listed on the ASX and NASDAQ and expects to generate "just
Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622 million. Lead asset TLX591-Tx advances in phase 3 for mCRPC, while TLX250-Tx targets ccRCC in both monotherapy and combination trials.
MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innovations in PSMA-PET/CT imaging for prostate cancer.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI).
Telix's revenue grew by 56% in 2025. The Australian company develops drugs that can both detect and treat cancers.
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate.
Telix Pharmaceuticals (NASDAQ: TLX - Get Free Report) is expected to be announcing its H2 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of $0.0493 per share and revenue of $421.5040 million for the quarter. Investors can find conference call details on the company's upcoming H2 2025
Telix Pharmaceuticals Limited (NASDAQ: TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
NEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.